Cymabay Therapeutics Inc reports results for the quarter ended in December - Earnings Summary

CymaBay Therapeutics

16/03/2023 21:01

* Cymabay Therapeutics Inc  CBAY.OQ  reported a quarterly
adjusted
loss of 30 cents​​ per share for the quarter ended in December.
The mean expectation of ten analysts for the quarter was for a
loss of 30 cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * Cymabay Therapeutics Inc's reported EPS for the quarter
was a
loss of 30 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Cymabay Therapeutics Inc shares had risen by 44.7% this
quarter.
    * The company reported a quarterly loss of $26.63 million.
    * Wall Street's median 12-month price target for Cymabay
Therapeutics Inc is $12.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 10 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 16 at 09:00 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.30          -0.30          Met
 Sep. 30 2022      -0.30          -0.28          Beat
 Jun. 30 2022      -0.30          -0.31          Missed
 Mar. 31 2022      -0.31          -0.32          Missed